Literature DB >> 22461638

Raising the bar: the curative potential of human cancer immunotherapy.

Steven A Rosenberg1.   

Abstract

Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22461638      PMCID： PMC6292198          DOI： 10.1126/scitranslmed.3003634

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  41 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

2.  Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

Authors:  Ling Zhang; Sid P Kerkar; Zhiya Yu; Zhili Zheng; Shicheng Yang; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 4.  Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

Authors:  Steven A Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2011-08-02       Impact factor: 66.675

5.  T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

Authors:  Maria R Parkhurst; James C Yang; Russell C Langan; Mark E Dudley; Debbie-Ann N Nathan; Steven A Feldman; Jeremy L Davis; Richard A Morgan; Maria J Merino; Richard M Sherry; Marybeth S Hughes; Udai S Kammula; Giao Q Phan; Ramona M Lim; Stephen A Wank; Nicholas P Restifo; Paul F Robbins; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-12-14       Impact factor: 11.454

6.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

7.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Authors:  G Gross; T Waks; Z Eshhar
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

8.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

9.  Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

Authors:  S A Rosenberg; J C Yang; D E White; S M Steinberg
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

10.  Structure and expression of a cloned cDNA for human interleukin-2.

Authors:  T Taniguchi; H Matsui; T Fujita; C Takaoka; N Kashima; R Yoshimoto; J Hamuro
Journal:  Nature       Date:  1983 Mar 24-30       Impact factor: 49.962
View more
  119 in total

Review 1.  Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.

Authors:  X Wang; I Rivière
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

2.  Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy.

Authors:  Rachel E Beard; Daniel Abate-Daga; Shannon F Rosati; Zhili Zheng; John R Wunderlich; Steven A Rosenberg; Richard A Morgan
Journal:  Clin Cancer Res       Date:  2013-09-10       Impact factor: 12.531

Review 3.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

4.  Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells.

Authors:  Francesca Giannoni; Cinnamon L Hardee; Jennifer Wherley; Eric Gschweng; Shantha Senadheera; Michael L Kaufman; Rebecca Chan; Ingrid Bahner; Vivian Gersuk; Xiaoyan Wang; David Gjertson; David Baltimore; Owen N Witte; James S Economou; Antoni Ribas; Donald B Kohn
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

Review 5.  Immunotherapeutic strategies to target prognostic and predictive markers of cancer.

Authors:  Michael S Magee; Adam E Snook; Glen P Marszalowicz; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

6.  N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner.

Authors:  Matthew J Scheffel; Gina Scurti; Megan M Wyatt; Elizabeth Garrett-Mayer; Chrystal M Paulos; Michael I Nishimura; Christina Voelkel-Johnson
Journal:  Cancer Immunol Immunother       Date:  2018-02-02       Impact factor: 6.968

7.  Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L.

Authors:  C Marcela Díaz-Montero; Abdel-Aziz Zidan; Maria F Pallin; Vasileios Anagnostopoulos; Mohamed L Salem; Eric Wieder; Krishna Komanduri; Alberto J Montero; Mathias G Lichtenheld
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

8.  Clinical significance of immunotherapy with combined three kinds of cells for operable colorectal cancer.

Authors:  Xiao-Hui Du; Hai-Liang Liu; Li Li; Shao-You Xia; Ning Ning; Zhen-Yu Zou; Da Teng; Chun-Hong Xiao; Rong Li; Ying-Xin Xu
Journal:  Tumour Biol       Date:  2015-03-13

Review 9.  Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.

Authors:  André Ballesteros-Tato
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

10.  Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin.

Authors:  Jessica J O'Konek; Elena Ambrosino; Anja C Bloom; Lise Pasquet; Chandirasegaran Massilamany; Zheng Xia; Masaki Terabe; Jay A Berzofsky
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.